Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Study Overview
=================
Brief Summary
-----------------
A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).

Official Title
-----------------
Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: H1N1 influenza A Vaccine (PANFLU.1)
* Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or female aged between 18 and 60 Be able to show legal identity card for the sake of recruitment Volunteers are able to understand and sign the informed consent Exclusion Criteria: Cases, cured cases and close contact of influenza A (H1N1) virus History of H1N1 vaccine or seasonal influenza vaccine administration Women of pregnancy, lactation or about to be pregnant in 60 days Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain Autoimmune disease or immunodeficiency Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids Diabetes mellitus (type I or II), with the exception of gestational diabetes History of thyroidectomy or thyroid disease that required medication within the past 12 months Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study Seizure disorder other than: Febrile seizures under the age of two years old Seizures secondary to alcohol withdrawal more than 3 years ago, or A singular seizure not requiring treatment within the last 3 years Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen Guillain-Barre Syndrome Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis) History of any blood products within 3 months before the dosing Administration of any other investigational research agents within 30 days before the dosing Administration of any live attenuated vaccine within 30 days before the dosing Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing Be receiving anti-TB prophylaxis or therapy currently Axillary temperature > 37.0 centigrade at the time of dosing Psychiatric condition that precludes compliance with the protocol: Past or present psychoses Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years Disorder requiring lithium Suicidal ideation occurring within five years prior to enrollment Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1: Day 0-PANFLU.1; Day 21-ANFLU<br>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine. | Biological: H1N1 influenza A Vaccine (PANFLU.1)<br>* H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)<br>Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)<br>* Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)<br>|
| Experimental: Group 2: Day 0-ANFLU; Day 21-PANFLU.1<br>50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine. | Biological: H1N1 influenza A Vaccine (PANFLU.1)<br>* H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)<br>Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)<br>* Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)<br>|
| Experimental: Group 3: Day 0-PANFLU.1+ANFLU<br>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine. | Biological: H1N1 influenza A Vaccine (PANFLU.1)<br>* H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)<br>Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)<br>* Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults |  | 3 months | 
| Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults |  | 3 months |